Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free treatments for ocular inflammatory diseases, filed and upsized an NYSE American IPO in mid-2026 targeting roughly $45–50 million at $8–10 per share, implying a post-IPO market capitalization near $294–299 million. Despite F-1 amendments and a planned July 15 pricing, the offering did not close as scheduled. With August now half over and no updated S-1 or roadshow activity reported, traders assign 98.6% probability to no IPO before September 2026. This pricing reflects persistent weakness in the small-cap biotech primary market, elevated volatility in comparable names, and the absence of fresh positive catalysts such as Phase 3 data or partnership announcements that could reopen the window. A near-term reversal would require either rapid stabilization in IPO sentiment or company-specific progress sufficient to revive underwriter interest before the September cutoff.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日2026年9月以前にIPOなし 98.6%
4億ドル～4億5千万ドル 2.9%
2億5千万ドル〜3億ドル 2.2%
3億5000万ドル〜4億ドル 1.8%
$15,117 Vol.
$15,117 Vol.
2026/07/09
2億5,000万ドル未満
<1%
2億5千万ドル〜3億ドル
2%
3億ドル〜3億5千万ドル
<1%
3億5000万ドル〜4億ドル
2%
4億ドル～4億5千万ドル
3%
4億5,000万ドル超
<1%
2026年9月以前にIPOなし
99%
2026年9月以前にIPOなし 98.6%
4億ドル～4億5千万ドル 2.9%
2億5千万ドル〜3億ドル 2.2%
3億5000万ドル〜4億ドル 1.8%
$15,117 Vol.
$15,117 Vol.
2026/07/09
2億5,000万ドル未満
$907 Vol.
<1%
2億5千万ドル〜3億ドル
$979 Vol.
2%
3億ドル〜3億5千万ドル
$561 Vol.
<1%
3億5000万ドル〜4億ドル
$561 Vol.
2%
4億ドル～4億5千万ドル
$349 Vol.
3%
4億5,000万ドル超
$680 Vol.
<1%
2026年9月以前にIPOなし
$11,080 Vol.
99%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free treatments for ocular inflammatory diseases, filed and upsized an NYSE American IPO in mid-2026 targeting roughly $45–50 million at $8–10 per share, implying a post-IPO market capitalization near $294–299 million. Despite F-1 amendments and a planned July 15 pricing, the offering did not close as scheduled. With August now half over and no updated S-1 or roadshow activity reported, traders assign 98.6% probability to no IPO before September 2026. This pricing reflects persistent weakness in the small-cap biotech primary market, elevated volatility in comparable names, and the absence of fresh positive catalysts such as Phase 3 data or partnership announcements that could reopen the window. A near-term reversal would require either rapid stabilization in IPO sentiment or company-specific progress sufficient to revive underwriter interest before the September cutoff.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
マーケット開始日： Jul 7, 2026, 9:12 AM ET
音量
$15,117終了日
2026/07/09マーケット開始日
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free treatments for ocular inflammatory diseases, filed and upsized an NYSE American IPO in mid-2026 targeting roughly $45–50 million at $8–10 per share, implying a post-IPO market capitalization near $294–299 million. Despite F-1 amendments and a planned July 15 pricing, the offering did not close as scheduled. With August now half over and no updated S-1 or roadshow activity reported, traders assign 98.6% probability to no IPO before September 2026. This pricing reflects persistent weakness in the small-cap biotech primary market, elevated volatility in comparable names, and the absence of fresh positive catalysts such as Phase 3 data or partnership announcements that could reopen the window. A near-term reversal would require either rapid stabilization in IPO sentiment or company-specific progress sufficient to revive underwriter interest before the September cutoff.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
音量
$15,117終了日
2026/07/09マーケット開始日
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma, a clinical-stage Israeli biotech developing steroid-free treatments for ocular inflammatory diseases, filed and upsized an NYSE American IPO in mid-2026 targeting roughly $45–50 million at $8–10 per share, implying a post-IPO market capitalization near $294–299 million. Despite F-1 amendments and a planned July 15 pricing, the offering did not close as scheduled. With August now half over and no updated S-1 or roadshow activity reported, traders assign 98.6% probability to no IPO before September 2026. This pricing reflects persistent weakness in the small-cap biotech primary market, elevated volatility in comparable names, and the absence of fresh positive catalysts such as Phase 3 data or partnership announcements that could reopen the window. A near-term reversal would require either rapid stabilization in IPO sentiment or company-specific progress sufficient to revive underwriter interest before the September cutoff.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問